Use of Interleukin-2 in the Management of Haematological Malignancies: Focus on Minimal Residual Disease

By Mandelli F.   Capria S.   Vignetti M.   Meloni G.  

BioDrugs, Vol. 12, Iss. 1, 1999-07 ,pp. : 43-53

Adis International

Access to resources Recommend Favorite

An Overview of Gene Therapy Approaches to Neurological Malignancies

By Izquierdo M.L.  

BioDrugs, Vol. 9, Iss. 4, 1998-04 ,pp. : 337-349

Adis International

Access to resources Recommend Favorite

Pilot clinical trial of an anti-TNF monoclonal antibody for the treatment of septic shock

By BOILLOT A   CAPELLIER G   RACADOT E   WIJDENES J   HERVE P   BARALE F  

Clinical Intensive Care, Vol. 6, Iss. 2, 1995-04 ,pp. : 52-52

Ashgate Publishing Ltd

Access to resources Recommend Favorite

New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

By Robak Tadeusz   Robak Ewa  

BioDrugs, Vol. 25, Iss. 1, 2011-02 ,pp. : 13-25

Adis International

Access to resources Recommend Favorite

Omalizumab: Anti-IgE monoclonal antibody E25, E25, Humanised anti-IgE MAb, IGE 025, Monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25

By  

BioDrugs, Vol. 16, Iss. 5, 2002-01 ,pp. : 380-386

Adis International

Access to resources Recommend Favorite